ABMC Awarded Drug Testing Contract in Missouri

KINDERHOOK, N.Y.--(BUSINESS WIRE)--Oct. 17, 2007--American Bio Medica Corporation (NASDAQ: ABMC) announced today that they have been notified by the Office of State Courts Administrator of the Supreme Court of Missouri that they have been awarded a contract to supply drug courts in the State of Missouri with ABMC's point of collection drug testing products, more specifically its Rapid TOX(R) and Rapid Drug Screen(R) products. ABMC's devices will be used in drug courts located throughout the State of Missouri.

There are currently 108 drug court programs in the State of Missouri with approximately 3,000 participants. The contract began in late September 2007 and will run through late September 2008. While the Company cannot put a value on the contract for the coming year, last year the State of Missouri drug court programs spent in excess of $300,000 for their drug testing supplies.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen, Rapid One(R), Rapid TEC(R), RDS(R) InCup(R) and Rapid TOX products test for the presence or absence of drugs of abuse in urine, while OralStat(R) and Rapid STAT(TM) tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader(R) is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company's dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-KSB for the fiscal year ended December 31, 2006, and quarterly reports on Form 10-QSB on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

    CONTACT: American Bio Medica Corporation
             Stan Cipkowski
             Chief Executive Officer
             (800) 227-1243, Ext 106

    SOURCE: American Bio Medica Corporation